comparemela.com

Latest Breaking News On - Pierluigi antonelli - Page 1 : comparemela.com

Fresenius : Appoints Internationally Experienced Biopharma Expert to the Fresenius Kabi Management Board

Contact Nicole Weber T +49 6172 686-2394 nicole.weber@fresenius.com Documents .

Mannheim
Baden-wüberg
Germany
Saarland
Heidelberg
Bad-homburg
Hessen
Utah
United-states
Seoul
Soult-ukpyolsi
South-korea

BIAL appoints Pierluigi Antonelli as Non-Executive Board Member

Porto, April 24, 2024 - BIAL, a hundred-year-old innovation-driven biopharmaceutical company focused on neurology, has announced the appointment of Pierluigi Antonelli, Fresenius Management Board member and Chairman & CEO of Fresenius Kabi, as a non-executive member of its Board of Directors. Antonio Horta-.

Coted-ivoire
Portugal
Mozambique
Panama
Italy
Switzerland
Angola
United-states
United-kingdom
Porto
Spain
Germany

FDA approves second tocilizumab biosimilar; first available in IV, subcutaneous forms

FDA approves second tocilizumab biosimilar; first available in IV, subcutaneous forms
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Shenaz-bagha
Fresenius-kabi
Pierluigi-antonelli
Genentech

Fresenius debuts Actemra biosimilar

Tyenne, for use in the treatment of chronic autoimmune diseases, is available in an intravenous formulation.

Bio-pharma
Michael-sen
Pierluigi-antonelli
Fresenius-kabi
Fresenius

European Commission Approves First Tocilizumab Biosimilar

The biosimilar, commercially called Tyenne, is indicated to treat several autoimmune diseases as well as cytokine release syndrome and COVID-19.

Fresenius-kabi
Pierluigi-antonelli
Drug-administration
European-medicines-agency
European-commission
European-union
Chief-executive-officer-pierluigi-antonelli
Biologic-license-application
Rheumatoid-arthritis
A
Biologic-therapy
Biosimilars

vimarsana © 2020. All Rights Reserved.